Monopar Therapeutics (MNPR) Shares Outstanding (2016 - 2025)

Monopar Therapeutics has disclosed Shares Outstanding across 10 years of filings, most recently posting $6.7 million for Q4 2025.

• Shares Outstanding for Q4 2025 came in at $6.7 million, up 9.66% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.7 million (up 9.66% YoY), and the FY2025 annual result was $6.7 million, up 9.66% from the prior year.
• Shares Outstanding came in at $6.7 million for Q4 2025 at Monopar Therapeutics, roughly flat from $6.7 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $12.9 million in Q3 2022 to a low of $2.6 million in Q4 2022.
• The 5-year median for Shares Outstanding is $6.1 million (2025), against an average of $7.2 million.
• Across the five-year window, Shares Outstanding plunged 79.45% in 2022 and soared 533.25% in 2024, its largest moves.
• Monopar Therapeutics' Shares Outstanding stood at $12.6 million in 2021, then slumped by 79.45% to $2.6 million in 2022, then increased by 15.12% to $3.0 million in 2023, then jumped by 104.72% to $6.1 million in 2024, then grew by 9.66% to $6.7 million in 2025.
• The last three Shares Outstanding figures came in at $6.7 million (Q4 2025), $6.7 million (Q3 2025), and $6.1 million (Q2 2025), per Business Quant data.